Physician profile
Stephen R Chen
NPI 1396798500
$21,687.42
in general payments reported to CMS, 2019-2025
24 companies · $3,295 in 2025
The $3,295 reported for 2025 was more than what 81% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,988 · 2020: $113 · 2021: $10K · 2022: $900 · 2023: $3,360 · 2024: $1,800 · 2025: $3,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,523 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,800 · Travel and Lodging: $1,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,523.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,800.00 |
| Travel and Lodging | $1,132.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Balt USA, LLC | $10,535.11 | 2020-2025 | Optima Coil System, Prestige Coil System, Carrier Delivery Catheter |
| Boston Scientific Corporation | $3,391.31 | 2021-2025 | Obsidio, Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Penumbra, INC. | $2,674.97 | 2020-2025 | Penumbra System, Indigo System, Red 72 |
| Stryker Corporation | $2,502.13 | 2019-2025 | Spinejack, Flowtriever, Optablate |
| Depuy Synthes Sales INC. | $315.27 | 2024-2025 | Trufill, Emboguard |
| Qapel Medical INC | $264.71 | 2023 | |
| Medical Device Business Services, INC. | $262.40 | 2025 | |
| Inspiremd LTD | $261.32 | 2025 | Cguard Prime Carotid Stent System |
| Microvention, INC. | $223.01 | 2019-2024 | Hydrosoft Advanced, Stent, Sofia 6f-131cm Str |
| Medtronic, INC. | $159.34 | 2023 | Osteocool Rf Ablation System |
| Trisalus Life Sciences, INC. | $154.19 | 2022 | |
| Angiodynamics, INC. | $149.63 | 2023 | Alphavac |
| Delcath Systems | $139.99 | 2024 | Hepzato Kit |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019 | |
| Medtronic USA, INC. | $114.38 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $113.19 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.83 | 2025 | |
| Silk Road Medical, INC. | $73.53 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Imperative Care, INC | $40.06 | 2025 | Zoom Reperfusion Catheter |
| Stemline Therapeutics INC. | $23.08 | 2023 | Orserdu |
| Inari Medical, INC. | $18.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.00 | 2019 | |
| Perfuze INC | $16.82 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.